Michael J Zelefsky1, Bing Ying Poon2, James Eastham3, Andrew Vickers2, Xin Pei4, Peter T Scardino3. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: zelefskm@mskcc.org. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Abstract
PURPOSE: We evaluated quality-of-life changes (QoL) in 907 patients treated with either radical prostatectomy (open or laparoscopic), real-time planned conformal brachytherapy, or high-dose intensity-modulated radiotherapy (IMRT) on a prospective IRB-approved longitudinal study. METHODS: Validated questionnaires given pretreatment (baseline) and at 3, 6, 9, 12, 15, 18, 24, 36, and 48 months addressed urinary function, urinary bother, bowel function, bowel bother, sexual function, and sexual bother. RESULTS: At 48 months, surgery had significantly higher urinary incontinence than others (both P<.001), but fewer urinary irritation/obstruction symptoms (all P<.001). Very low levels of bowel dysfunction were observed and only small subsets in each group showed rectal bleeding. Brachytherapy and IMRT showed better sexual function than surgery accounting for baseline function and other factors (delta 14.29 of 100, 95% CI, 8.57-20.01; and delta 10.5, 95% CI, 3.78-17.88). Sexual bother was similar. Four-year outcomes showed persistent urinary incontinence for surgery with more obstructive urinary symptoms for radiotherapy. Using modern radiotherapy delivery, bowel function deterioration is less-often observed. Sexual function was strongly affected in all groups yet significantly less for radiotherapy. CONCLUSIONS: Treatment selection should include patient preferences and balance predicted disease-free survival over a projected time vs potential impairment of QoL important for the patient.
PURPOSE: We evaluated quality-of-life changes (QoL) in 907 patients treated with either radical prostatectomy (open or laparoscopic), real-time planned conformal brachytherapy, or high-dose intensity-modulated radiotherapy (IMRT) on a prospective IRB-approved longitudinal study. METHODS: Validated questionnaires given pretreatment (baseline) and at 3, 6, 9, 12, 15, 18, 24, 36, and 48 months addressed urinary function, urinary bother, bowel function, bowel bother, sexual function, and sexual bother. RESULTS: At 48 months, surgery had significantly higher urinary incontinence than others (both P<.001), but fewer urinary irritation/obstruction symptoms (all P<.001). Very low levels of bowel dysfunction were observed and only small subsets in each group showed rectal bleeding. Brachytherapy and IMRT showed better sexual function than surgery accounting for baseline function and other factors (delta 14.29 of 100, 95% CI, 8.57-20.01; and delta 10.5, 95% CI, 3.78-17.88). Sexual bother was similar. Four-year outcomes showed persistent urinary incontinence for surgery with more obstructive urinary symptoms for radiotherapy. Using modern radiotherapy delivery, bowel function deterioration is less-often observed. Sexual function was strongly affected in all groups yet significantly less for radiotherapy. CONCLUSIONS: Treatment selection should include patient preferences and balance predicted disease-free survival over a projected time vs potential impairment of QoL important for the patient.
Authors: Thomas L Jang; Justin E Bekelman; Yihai Liu; Peter B Bach; Ethan M Basch; Elena B Elkin; Michael J Zelefsky; Peter T Scardino; Colin B Begg; Deborah Schrag Journal: Arch Intern Med Date: 2010-03-08
Authors: David C Miller; Martin G Sanda; Rodney L Dunn; James E Montie; Hector Pimentel; Howard M Sandler; William P McLaughlin; John T Wei Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Ida J Korfage; Marie-Louise Essink-Bot; Gerard J J M Borsboom; Joanna B Madalinska; Wim J Kirkels; J Dik F Habbema; Fritz H Schröder; Harry J de Koning Journal: Int J Cancer Date: 2005-08-20 Impact factor: 7.396
Authors: Christie A Befort; Michael J Zelefsky; Peter T Scardino; Evelinn Borrayo; R Brian Giesler; Michael W Kattan Journal: Clin Prostate Cancer Date: 2005-09
Authors: Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino Journal: J Clin Oncol Date: 2010-02-16 Impact factor: 44.544
Authors: Pirus Ghadjar; Andrew Jackson; Daniel E Spratt; Jung Hun Oh; Per Munck af Rosenschöld; Marisa Kollmeier; Ellen Yorke; Margie Hunt; Joseph O Deasy; Michael J Zelefsky Journal: Eur Urol Date: 2013-02-14 Impact factor: 20.096
Authors: Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei Journal: N Engl J Med Date: 2008-03-20 Impact factor: 91.245
Authors: Mark S Litwin; John L Gore; Lorna Kwan; Judson M Brandeis; Steve P Lee; H Rodney Withers; Robert E Reiter Journal: Cancer Date: 2007-06-01 Impact factor: 6.860
Authors: Daniel A Barocas; JoAnn Alvarez; Matthew J Resnick; Tatsuki Koyama; Karen E Hoffman; Mark D Tyson; Ralph Conwill; Dan McCollum; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Mia Hashibe; Sherrie H Kaplan; Lisa E Paddock; Antoinette M Stroup; Xiao-Cheng Wu; David F Penson Journal: JAMA Date: 2017-03-21 Impact factor: 56.272
Authors: Oscar Casares-Magaz; Ludvig Paul Muren; Vitali Moiseenko; Stine E Petersen; Niclas Johan Pettersson; Morten Høyer; Joseph O Deasy; Maria Thor Journal: Acta Oncol Date: 2017-09-08 Impact factor: 4.089
Authors: Karen E Hoffman; David F Penson; Zhiguo Zhao; Li-Ching Huang; Ralph Conwill; Aaron A Laviana; Daniel D Joyce; Amy N Luckenbaugh; Michael Goodman; Ann S Hamilton; Xiao-Cheng Wu; Lisa E Paddock; Antoinette Stroup; Matthew R Cooperberg; Mia Hashibe; Brock B O'Neil; Sherrie H Kaplan; Sheldon Greenfield; Tatsuki Koyama; Daniel A Barocas Journal: JAMA Date: 2020-01-14 Impact factor: 56.272
Authors: Bradley J Stish; Brian J Davis; Lance A Mynderse; Robert H McLaren; Christopher L Deufel; Richard Choo Journal: Transl Androl Urol Date: 2018-06
Authors: Joanne W Jang; Michael R Drumm; Jason A Efstathiou; Jonathan J Paly; Andrzej Niemierko; Marek Ancukiewicz; James A Talcott; Jack A Clark; Anthony L Zietman Journal: Cancer Med Date: 2017-05-31 Impact factor: 4.452